Interleukin 17-producing T-helper cells and autoimmune diseases: Time for a paradigm shift?

Current Rheumatology Reports

Volumn 9, Issue 2, 2007, Pages 93-95

  Yamamura, Takashi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

ASTHMA; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; DERMATITIS; HELPER CELL; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; RHEUMATOID ARTHRITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-7; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34250621465     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0001-6     Document Type: Note

References (20)

1. Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
2. Panitch HS, Bever CT Jr: Clinical trials of interferons in multiple sclerosis. What have we learned? J Neuroimmunol 1993, 46:155-164.
3. Bielekova B, Goodwin B, Richert N, et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
4. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
5. McKenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006, 27:17-23.
6. Langrish CL, Chen Y, Blumenschein WM, et al.: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
7. Harrington LE, Hatton RD, Mangan PR, et al.: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
8. Park H, Li Z, Yang XO, et al.: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
9. Yen D, Cheung J, Scheerens H, et al.: IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
10. Veldhoen M, Hocking RJ, Atkins CJ, et al.: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
11. Bettelli E, Carrier Y, Gao W, et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
12. Mangan PR, Harrington LE, O'Quinn DB, et al.: Transforming growth factor-β induces development of the TH17 lineage. Nature 2006, 441:231-234.
13. Komiyama Y, Nakae S, Matsuki T, et al.: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
14. Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
15. Nishimoto N, Kanakura Y, Aozasa K, et al.: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106:2627-2632.
16. Batten M, Ki J, Yi S, et al.: Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006, 7:929-936.
17. Stumhofer JS, Laurence A, Wilson EH, et al.: Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006, 7:937-945.
18. Ishizu T, Osoegawa M, Mei FJ, et al.: Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128(Pt 5):988-1002.
19. Chen Y, Langrish CL, McKenzie B, et al.: Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameriolates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.
20. Satoh J, Nanri Y, Tabunoki H, Yamamura T: Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol 2006, 6:18.